// App-Quantinova.ai

513.0 : Validation of MAF biomarker for response prediction to adjuvant bisphosphonates in 2 clinical trials: AZURE and NSABP-B34.

Researchers

Presenter

  • Alexander H. G. Paterson

Principal Investigators

  • Stewart J. Anderson

  • Roger Gomis

  • Joel Jean

  • Juan-Carlos Tercero

  • Peter Lucas

  • Eleftherios P. Mamounas

Medical Centers

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA

  • Universitat de Barcelona, Barcelona, Spain

  • Inbiomotion SL, Barcelona, Spain

  • NSABP, Pittsburgh, PA

  • NSABP, and The Orlando Health UF Health Cancer Center, Orlando, FL

Locations

  • Canada

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Transcription factor Maf

Drug/Treatment

  • Clodronate disodium

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved